Company Profile

  • Mr.sir
    Tel: +41 61 316 81 11、800-638-8174 、+32 87 321 611

  • Mobile:
  • Tel:+41 61 316 81 11、800-638-8174 、+32 87 321 611
  • Fax:
  • Province/state:
  • City:
  • Street:muenchensteinerstrasse 38 ch-4002 basel
  • MaxCard:
    About us

  • Welcome To Our Site!

  • Lonza invests ￡16 million to further develop the flexibility and capability of its Slough, UK biopharmaceutical manufacturing facility to respond to a broader range of customer projects and strengthen its global network of biologics development and manufacturing. The project is scheduled for completion by the end of 2012.
    Lonza plans to invest CHF 24 million to expand cytotoxic manufacturing capabilities in Visp, Switzerland to serve growing oncology API market. Cytotoxic APIs are commonly used in oncology therapeutics, which represent one of the fastest growing segments of the pharma and biotech industry.
    Lonza expands its viral-based therapeutics business with the construction of a new, state-of-the-art cGMP clean room located adjacent to its existing Houston, Texas operations.
    Lonza is investing CHF 10 million to expand its biopharmaceutical development services platform in Singapore to meet increasing demand for biopharma development services from preclinical to commercial.
    Lonza invests CHF 5.8 million in a formulation plant for Meta? metaldehyde. This will enable Lonza to supply its own formulations, allowing the company in the future to serve the market not only with metaldehyde as an active substance, but also with ready-made slug pellets. It is expected to become operational in the second half of 2012.
    Lonza celebrates 40 years as leading producer of vitamin B3. Since 1971, Lonza has supplied more than half the world’s demand for vitamin B3 in the human and animal health nutrition industries.
    Lonza Group Ltd and global regenerative medicine company Mesoblast Limited enter into a strategic alliance for clinical and long-term commercial production of Mesoblast’s off-the-shelf (allogeneic) adult stem cell products.
    Lonza acquires Arch Chemicals, Inc., a global biocides company providing innovative solutions to destroy or to selectively inhibit the growth of harmful microorganisms, to create the world’s leading Microbial Control business. The combined businesses will be able to develop innovative microbial control formulations based on a broad portfolio of registered and approved active ingredients. Jeanne Thoma is appointed to Chief Operating Officer for Lonza’s Microbial Control sector (LMC) which will be created following the acquisition.
    Lonza Group Ltd (SIX stock code: LONN VX; SGX-ST stock code: O6Z) makes its trading debut on the Main Board of the Singapore Exchange Securities Trading Limited (“SGX-ST”) on 21 October 2011 and consequently is the first SIX Swiss-listed company to dual list in Singapore.
    Lonza to expand early phase manufacturing capacity at its site in Nansha, China, to serve small molecules market.

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog